Template:Pyrazinamide: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Chetan Lokhande (talk | contribs)
nocaptcha
4,484 edits
No edit summary
Chetan Lokhande (talk | contribs)
nocaptcha
4,484 edits
No edit summary
Line 7: Line 7:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide clinical pharmacology|Clinical Pharmacology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide microbiology|Microbiology]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide indications and usage|Indications and Usage]]
Line 19: Line 17:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide overdosage|Overdosage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide dosage and administration|Dosage and Administration]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide how supplied|How Supplied]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide how supplied|How Supplied]]

Revision as of 02:16, 4 January 2014

Pyrazinamide
FDA Package Insert (MIKART®)
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages
Retrieved from "https://www.wikidoc.org/index.php?title=Template:Pyrazinamide&oldid=923937"